Chuying Wang1, Jiao Yu2, Yangwei Fan1, Ke Ma1, Jing Ning1, Yuan Hu1, Wenxia Niu1, Xuyuan Dong1, Yinying Wu1, Enxiao Li1, Danfeng Dong3. 1. Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an. 2. Department of Radiotherapy, Shaanxi Provincial People' Hospital, Xi'an, Shaanxi, China. 3. Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an qiwudanfeng@sina.com doclienxiao@163.com.
Abstract
PURPOSE: This study examined the tumor expression of programmed cell death ligand 1 (PD-L1)/programmed cell death protein 1 (PD-1) in patients with GEP-NEN. This study aims to reveal the relationship of their expression with clinicopathological characteristics and prognosis. METHODS: PD1 and PD-L1 expression in tumors from 120 GEP-MEN patients was evaluated using immunohistochemistry. The correlations of the expression of PDL1/PD1 and clinicopathological features were assessed. RESULTS: Immunohistochemical staining indicated that PD-L1 was expressed in the tumor cells of 52.5% patients with GEP-NENs, and PD-L1 expression was positively correlated with the World Health Organization (WHO) classification, American Joint Committee on Cancer (AJCC) stage, lymphatic metastasis and prognosis. Meanwhile, PD-1 was expressed in tumor infiltrating lymphocytes within 55.8% tumor samples, and PD-1 expression was positively correlated with AJCC stage and GEP-NENs prognosis. Moreover, survival analysis indicated that the overall median survival of patients with PD-L1/PD-1-positive tumors significantly differed from that of patients with PD-L1/PD-1-negative tumors. Multivariate analysis confirmed that AJCC stage and Chromogranin A expression in tumor tissues were independent prognostic factors for overall survival. In conclusion, PDL1 was an independent prognostic factor for patients with GEP-NENs. Our results suggested that patients with GEP-NENs might be appropriate for PD1/PDL1-targeted therapy. CONCLUSIONS: Our findings show that the expression of PD-L1 and PD-1 correlates with patient prognosis, and may thus serve as potential pathological prognostic markers of GEP-NENs. Immunotherapy using PD-1/PD-L1 inhibitors may be a promising strategy for GEP-NENs patients with PD-L1/PD-1 positively expressed.
PURPOSE: This study examined the tumor expression of programmed cell death ligand 1 (PD-L1)/programmed cell death protein 1 (PD-1) in patients with GEP-NEN. This study aims to reveal the relationship of their expression with clinicopathological characteristics and prognosis. METHODS:PD1 and PD-L1 expression in tumors from 120 GEP-MENpatients was evaluated using immunohistochemistry. The correlations of the expression of PDL1/PD1 and clinicopathological features were assessed. RESULTS: Immunohistochemical staining indicated that PD-L1 was expressed in the tumor cells of 52.5% patients with GEP-NENs, and PD-L1 expression was positively correlated with the World Health Organization (WHO) classification, American Joint Committee on Cancer (AJCC) stage, lymphatic metastasis and prognosis. Meanwhile, PD-1 was expressed in tumor infiltrating lymphocytes within 55.8% tumor samples, and PD-1 expression was positively correlated with AJCC stage and GEP-NENs prognosis. Moreover, survival analysis indicated that the overall median survival of patients with PD-L1/PD-1-positive tumors significantly differed from that of patients with PD-L1/PD-1-negative tumors. Multivariate analysis confirmed that AJCC stage and Chromogranin A expression in tumor tissues were independent prognostic factors for overall survival. In conclusion, PDL1 was an independent prognostic factor for patients with GEP-NENs. Our results suggested that patients with GEP-NENs might be appropriate for PD1/PDL1-targeted therapy. CONCLUSIONS: Our findings show that the expression of PD-L1 and PD-1 correlates with patient prognosis, and may thus serve as potential pathological prognostic markers of GEP-NENs. Immunotherapy using PD-1/PD-L1 inhibitors may be a promising strategy for GEP-NENs patients with PD-L1/PD-1 positively expressed.
Authors: Alexander W MacFarlane; Ho-Man Yeung; R Katherine Alpaugh; Essel Dulaimi; Paul F Engstrom; Arvind Dasari; Kerry S Campbell; Namrata Vijayvergia Journal: Cancer Immunol Immunother Date: 2021-01-04 Impact factor: 6.630
Authors: Karen Rico; Suzann Duan; Ritu L Pandey; Yuliang Chen; Jayati T Chakrabarti; Julie Starr; Yana Zavros; Tobias Else; Bryson W Katona; David C Metz; Juanita L Merchant Journal: BMJ Open Gastroenterol Date: 2021-11
Authors: Sarah Krieg; Christoph Roderburg; Stephen Fung; Tom Luedde; Wolfram Trudo Knoefel; Andreas Krieg Journal: J Cancer Res Clin Oncol Date: 2022-04-15 Impact factor: 4.322